Therapeutic index improvement of antibody-drug conjugates

References

• Fuentes-Antras J, Genta S, Vijenthira A, Siu LL. Antibody–drug conjugates: in search of partners of choice. Trends Cancer. 2023;9(4):339–4. doi:10.1016/j.trecan.2023.01.003. PMID: 36746689.
   PubMed Web of Science ®Google Scholar
• Colombo R, Rich JR. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell. 2022;40(11):1255–63. doi:10.1016/j.ccell.2022.09.016. PMID: 36240779.
   PubMed Web of Science ®Google Scholar
• Mahalingaiah PK, Ciurlionis R, Durbin KR, Yeager RL, Philip BK, Bawa B, Mantena SR, Enright BP, Liguori MJ, Van Vleet TR. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacology & Therapeutics. 2019;200:110–25. doi:10.1016/j.pharmthera.2019.04.008. PMID: 31028836.
   PubMed Web of Science ®Google Scholar
• Saber H, Leighton JK. An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol. 2015;71:444–52. doi:10.1016/j.yrtph.2015.01.014. PMID: 25661711.
   PubMed Web of Science ®Google Scholar
• King GT, Eaton KD, Beagle BR, Zopf CJ, Wong GY, Krupka HI, Hua SY, Messersmith WA, El-Khoueiry AB. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018;36(5):836–47. doi:10.1007/s10637-018-0560-6. PMID: 29333575.
   PubMed Web of Science ®Google Scholar
• Munz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmuller G, et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int. 2010;10(1):44. doi:10.1186/1475-2867-10-44. PMID: 21044305.
   PubMedGoogle Scholar
• Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs. 2013;31(1):77–84. doi:10.1007/s10637-012-9801-2. PMID: 22370972.
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Morganti S, Curigliano G. Antibody–drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14(1):20. doi:10.1186/s13045-021-01035-z. PMID: 33509252.
   PubMed Web of Science ®Google Scholar
• Liu Y, Nguyen AW, Maynard JA. Engineering antibodies for conditional activity in the solid tumor microenvironment. Curr Opin Biotechnol. 2022;78:102809. doi:10.1016/j.copbio.2022.102809. PMID: 36182870.
   PubMed Web of Science ®Google Scholar
• Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, Senter PD. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19(3):759–65. doi:10.1021/bc7004329. PMID: 18314937.
   PubMed Web of Science ®Google Scholar
• Shen X, Liu X, Li T, Chen Y, Chen Y, Wang P, Zheng L, Yang H, Wu C, Deng S, et al. Recent advancements in serum albumin-based nanovehicles toward potential cancer diagnosis and therapy. Front Chem. 2021;9:746646. doi:10.3389/fchem.2021.746646. PMID: 34869202.
   PubMed Web of Science ®Google Scholar
• Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, Kawakami H, Tanaka K, Hayashi H, Takeda M, et al. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J Clin Invest. 2020;130:374–88. doi:10.1172/JCI126598. PMID: 31661465.
   PubMed Web of Science ®Google Scholar
• Sharkey MS, Lizee G, Gonzales MI, Patel S, Topalian SL. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Research. 2004;64(5):1595–99. https://www.ncbi.nlm.nih.gov/pubmed/14996715. PMID: 14996715.
   PubMed Web of Science ®Google Scholar
• Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn. 2013;40(5):557–71. doi:10.1007/s10928-013-9329-x. PMID: 23933716.
   PubMed Web of Science ®Google Scholar
• Muller PY, Milton MN. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov. 2012;11(10):751–61. doi:10.1038/nrd3801. PMID: 22935759.
   PubMed Web of Science ®Google Scholar
• Betts A, Clark T, Jasper P, Tolsma J, van der Graaf P H, Graziani EI, Rosfjord E, Sung M, Ma D, Barletta F, et al. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. J Pharmacokinet Pharmacodyn. 2020;47(5):513–26. doi:10.1007/s10928-020-09702-3. PMID: 32710210.
   PubMed Web of Science ®Google Scholar
• Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, Bouabdallah R, Pautas C, Turlure P, Reman O, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66–71. doi:10.1038/sj.leu.2404434. PMID: 17051246.
   PubMed Web of Science ®Google Scholar
• Liao MZ, Lu D, Kagedal M, Miles D, Samineni D, Liu SN, Li C. Model-Informed therapeutic dose optimization strategies for antibody–drug conjugates in oncology: what can we learn from us food and drug administration–approved antibody–drug conjugates? Clin Pharmacol Ther. 2021;110(5):1216–30. doi:10.1002/cpt.2278. PMID: 33899934.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37. doi:10.1038/nrd.2016.268. PMID: 28303026.
   PubMed Web of Science ®Google Scholar
• Graziani EI, Sung M, Ma D, Narayanan B, Marquette K, Puthenveetil S, Tumey LN, Bikker J, Casavant J, Bennett EM, et al. PF-06804103, a site-specific anti-HER2 antibody–drug conjugate for the treatment of HER2-expressing breast, gastric, and lung cancers. Mol Cancer Ther. 2020;19(10):2068–78. doi:10.1158/1535-7163.MCT-20-0237. PMID: 32747418.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Calvo E, Moreno V, Chung HC, Park YH, Bang Y-J, Rosen LS, Mita MM, Garrido-Laguna I, Leung ACF, et al. A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors. JCO. 2020;38(15_suppl):1039–1039. doi:10.1200/JCO.2020.38.15_suppl.1039.
   Web of Science ®Google Scholar
• Wang J, Liu Y, Qingyuan Z, Jifeng F, Fang J, Chen X, Han Y, Li Q, Zhang P, Yuan P, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. JCO. 2021;39(15_suppl):1022–1022. doi:10.1200/JCO.2021.39.15_suppl.1022.
   Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, et al. DS-8201a, a Novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097–108. doi:10.1158/1078-0432.CCR-15-2822. PMID: 27026201.
   PubMed Web of Science ®Google Scholar